Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab

Schmid, L; Müller, M; Treumann, T; Arnold, W; Möller, B; Aeberli, D; Villiger, P M (2009). Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab. Arthritis & rheumatism, 60(6), pp. 1632-4. Hoboken, N.J.: Wiley-Blackwell 10.1002/art.24577

Full text not available from this repository. (Request a copy)

Aseptic pachymeningitis is a rare and serious complication of rheumatoid arthritis (RA). Herein, we describe a patient with rheumatoid factor-positive and anti-cyclic citrullinated peptide-positive RA who experienced a focal seizure, with aphasia and convulsions of the right side of the body. The findings of magnetic resonance imaging and histologic analysis led to a diagnosis of rheumatoid pachymeningitis. Because the patient had a large number of CD20-expressing B lymphocytes, therapy with rituximab was started and has resulted in complete and sustained remission of both the pachymeningitis and the RA for >2 years. Despite a decrease in immunoglobulins, the patient has remained free of infections, which illustrates the favorable outcome that can result from therapeutic B cell depletion in this potentially lethal manifestation of RA.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Möller, Burkhard, Villiger, Peter Matthias








Factscience Import

Date Deposited:

04 Oct 2013 15:11

Last Modified:

05 Dec 2022 14:22

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 195914)

Actions (login required)

Edit item Edit item
Provide Feedback